EBMT 2024 | Preclinical research for the future of cellular therapies
Christian Chabannon, MD, PhD, Institut Paoli Calmettes, Marseille, France, shares insights from a session focusing on preclinical research for the future of cellular therapies. He underscores the potential of CARs, including structural modifications, transgene additions, and targeting diverse immune cells, along with exploring tissue infiltrating lymphocytes. This preclinical research paves the way for future therapies, and it will be intriguing to observe which advancements transition to market availability for patient benefit. This interview took place at the 50th Annual Meeting of the EBMT in Glasgow, Scotland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
This session was a sort of sci-fi session for the meeting where we had three presentations describing preclinical, early clinical and perspectives in the development of cellular therapies, and not only for hematological diseases is already happening in routine practice, but also for solid tumors.
So the technology holds really bright promise, and there is no limit to the imagination of scientists, translational and basic scientists...
This session was a sort of sci-fi session for the meeting where we had three presentations describing preclinical, early clinical and perspectives in the development of cellular therapies, and not only for hematological diseases is already happening in routine practice, but also for solid tumors.
So the technology holds really bright promise, and there is no limit to the imagination of scientists, translational and basic scientists. So you can basically modify the structure of a chimeric antigen receptor. You can couple the chimeric antigen receptor with other transgenes, you can modify the genome of the cells into which you insert the CAR, you can think of transferring a CAR not only to conventional T-cells, but to other types of immune effector cells. You can also think of collecting tissue infiltrating lymphocytes from patients with solid tumors, amplify activate these cells and turn them into a medicinal product.
So a lot of perspectives really stimulating discussion with the audience. And again, one of the question and $1 million question is how much of this will actually reach the market, make a commercial success and be available to patients. But that was really an exhilarating session where we heard excellent presentations from scientists and investigators.
Read more...
